Cart
sales@molnova.com
AEE-788
CAS No. 497839-62-0
AEE-788( AEE 788 | AEE788 | NVP-AEE 788 )
Catalog No. M14666 CAS No. 497839-62-0
A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 37 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 100 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 319 | In Stock |
|
| 100MG | 480 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1079 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAEE-788
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
-
DescriptionA potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively; inhibits growth factor-induced EGFR and ErbB2 phosphorylation in cells with IC50 of 11 and 220 nM, respectively, demonstrates antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines; shows antitumor and antiangiogenic activity in vivo.Brain Cancer Phase 2 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsAEE 788 | AEE788 | NVP-AEE 788
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptorc-Abl|c-Fms|EGFR|FLT1|HER2/ErbB2
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number497839-62-0
-
Formula Weight440.5832
-
Molecular FormulaC27H32N6
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@@H](NC1=C2C(NC(C3=CC=C(CN4CCN(CC)CC4)C=C3)=C2)=NC=N1)C5=CC=CC=C5
-
Chemical Name7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Traxler P, et al. Cancer Res. 2004 Jul 15;64(14):4931-41.
2. Goudar RK, et al. Mol Cancer Ther. 2005 Jan;4(1):101-12.
3. Park YW, et al. Clin Cancer Res. 2005 Mar 1;11(5):1963-73.
molnova catalog
related products
-
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
-
CGP77675
CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.
-
EGFR Inhibitor
EGFR inhibitor is a cell permeable and selective inhibitor of EGFR kinase (IC50: 21 nM) and blocks receptor autophosphorylation in cells.
